Caveolin-1–derived peptide limits development of pulmonary fibrosis-Reference-Cited by-同舟云学术

Caveolin-1–derived peptide limits development of pulmonary fibrosis

Published:2019-12-11 Issue:522 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Marudamuthu Amarnath Satheesh¹^ORCID,Bhandary Yashodhar Prabhakar¹^ORCID,Fan Liang¹^ORCID,Radhakrishnan Vijay¹^ORCID,MacKenzie BreAnne²,Maier Esther³,Shetty Shwetha Kumari¹^ORCID,Nagaraja M.R.¹^ORCID,Gopu Venkadesaperumal¹^ORCID,Tiwari Nivedita¹,Zhang Yajie³^ORCID,Watts Alan B.³^ORCID,Williams Robert O.³^ORCID,Criner Gerald J⁴,Bolla Sudhir⁴,Marchetti Nathaniel⁴,Idell Steven¹^ORCID,Shetty Sreerama¹^ORCID

Affiliation:

1. Department of Medicine, Texas Lung Injury Institute, University of Texas Health Science Center at Tyler, 11937 US Highway 271, Tyler, TX 75708, USA.

2. Lung Therapeutics Inc., 2801 Via Fortuna Suite 425 Austin, TX 78746, USA.

3. Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA.

4. Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, 3401 North Broad Street, Philadelphia, PA 19140, USA.

Abstract

CSP7, a caveolin-1–derived peptide, targets injured alveolar epithelial cells and activated lung fibroblasts to mitigate pulmonary fibrosis.

Funder

Flight Attendant Medical Research Institute

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference37 articles.

1. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

2. Epidemiology of idiopathic pulmonary fibrosis